Burkitt Lymphoma

Ann M Moormann1, Jeffrey A Bailey2, Rosemary Rochford3

  • 1Division of Immunology and Infectious Diseases, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA. ann.moormann@umassmed.edu.

Insights

Epstein-Barr virus (EBV) and Plasmodium falciparum (Pf) malaria coinfections in children may drive Burkitt lymphoma (BL) development. Malaria-induced immune changes could weaken surveillance, promoting EBV-driven BL tumorigenesis.

Area of Science:

  • Oncology
  • Virology
  • Immunology
  • Infectious Diseases

Background:

  • Burkitt lymphoma (BL) is a significant pediatric cancer in sub-Saharan Africa.
  • Epstein-Barr virus (EBV) is linked to BL, with a new classification distinguishing EBV-positive and negative tumors.
  • High incidence of EBV-positive BL correlates with Plasmodium falciparum (Pf) malaria coinfections in endemic regions.

Purpose of the Study:

  • To explore the link between Pf malaria coinfections and EBV-driven Burkitt lymphoma pathogenesis.
  • To understand how malaria-induced immune adaptations influence EBV persistence and BL development.

Main Methods:

  • Review of epidemiologic studies on EBV infections and Pf malaria.
  • Analysis of immune adaptations in children from malaria holoendemic regions.
  • Postulation of a mechanism involving immune conditioning, B cell proliferation, and EBV load.

Main Results:

  • Pf malaria infections directly impact EBV reactivation and persistence.
  • Chronic Pf malaria leads to immune adaptations to mitigate immunopathology.
  • These adaptations may result in diminished EBV-specific cellular immune surveillance.

Conclusions:

  • Malaria-induced immune conditioning, coupled with increased B cell proliferation and EBV load, creates a permissive environment for BL tumorigenesis.
  • Understanding this interplay is crucial for developing targeted prevention and treatment strategies for pediatric BL in endemic areas.